{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:30:40Z","timestamp":1780554640797,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":227,"publisher":"Springer US","isbn-type":[{"value":"9781071638897","type":"print"},{"value":"9781071638903","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3890-3_21","type":"book-chapter","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:02:18Z","timestamp":1718708538000},"page":"321-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["RNA-Based Vaccines and Therapeutics Against Intracellular Pathogens"],"prefix":"10.1007","author":[{"given":"Naga Suresh","family":"Kola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"9","key":"21_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727\u2013730. https:\/\/doi.org\/10.1038\/nrd892","journal-title":"Nat Rev Drug Discov"},{"issue":"6378","key":"21_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/357455a0","volume":"357","author":"AD Miller","year":"1992","unstructured":"Miller AD (1992) Human gene therapy comes of age. Nature 357(6378):455\u2013460. https:\/\/doi.org\/10.1038\/357455a0","journal-title":"Nature"},{"issue":"3","key":"21_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","volume":"57","author":"CM Perry","year":"1999","unstructured":"Perry CM, Barman Balfour JA (1999) Fomivirsen. Drugs 57(3):375\u2013380. https:\/\/doi.org\/10.2165\/00003495-199957030-00010","journal-title":"Drugs"},{"key":"21_CR4","doi-asserted-by":"publisher","unstructured":"Gragoudas ES, Cunningham ET, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805\u20132816. https:\/\/doi.org\/10.1056\/NEJMoa042760","DOI":"10.1056\/NEJMoa042760"},{"issue":"9","key":"21_CR5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1586\/erv.09.77","volume":"8","author":"L Redding","year":"2009","unstructured":"Redding L, Weiner DB (2009) DNA vaccines in veterinary use. Expert Rev Vaccines 8(9):1251\u20131276. https:\/\/doi.org\/10.1586\/erv.09.77","journal-title":"Expert Rev Vaccines"},{"key":"21_CR6","doi-asserted-by":"publisher","unstructured":"Curreri A, Sankholkar D, Mitragotri S, Zhao Z (2023) RNA therapeutics in the clinic. Bioeng Transl Med 8(1). https:\/\/doi.org\/10.1002\/btm2.10374","DOI":"10.1002\/btm2.10374"},{"key":"21_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.628137","volume":"9","author":"TR Damase","year":"2021","unstructured":"Damase TR et al (2021) The limitless future of RNA therapeutics. Front Bioeng Biotechnol 9:628137. https:\/\/doi.org\/10.3389\/fbioe.2021.628137","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"21_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhu L, Wang X, Jin H (2022) RNA-based therapeutics: an overview and prospectus. Cell Death Dis 13(7):644. https:\/\/doi.org\/10.1038\/s41419-022-05075-2","journal-title":"Cell Death Dis"},{"issue":"4","key":"21_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","volume":"54","author":"Y-K Kim","year":"2022","unstructured":"Kim Y-K (2022) RNA therapy: rich history, various applications and unlimited future prospects. Exp Mol Med 54(4):455\u2013465. https:\/\/doi.org\/10.1038\/s12276-022-00757-5","journal-title":"Exp Mol Med"},{"issue":"4776","key":"21_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/190576a0","volume":"190","author":"S Brenner","year":"1961","unstructured":"Brenner S, Jacob F, Meselson M (1961) An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190(4776):576\u2013581. https:\/\/doi.org\/10.1038\/190576a0","journal-title":"Nature"},{"key":"21_CR11","doi-asserted-by":"publisher","unstructured":"Chery J (2016) RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 4(7). https:\/\/doi.org\/10.14304\/SURYA.JPR.V4N7.5","DOI":"10.14304\/SURYA.JPR.V4N7.5"},{"issue":"10","key":"21_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694. https:\/\/doi.org\/10.1038\/s41573-020-0075-7","journal-title":"Nat Rev Drug Discov"},{"key":"21_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fgene.2019.00205","volume":"10","author":"LW Harries","year":"2019","unstructured":"Harries LW (2019) RNA biology provides new therapeutic targets for human disease. Front Genet 10:205. https:\/\/doi.org\/10.3389\/fgene.2019.00205","journal-title":"Front Genet"},{"issue":"1","key":"21_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/cells9010137","volume":"9","author":"S Bajan","year":"2020","unstructured":"Bajan S, Hutvagner G (2020) RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells 9(1):137. https:\/\/doi.org\/10.3390\/cells9010137","journal-title":"Cells"},{"key":"21_CR15","doi-asserted-by":"publisher","unstructured":"Moreno PMD, P\u00eago AP (2014) Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2. https:\/\/doi.org\/10.3389\/fchem.2014.00087","DOI":"10.3389\/fchem.2014.00087"},{"issue":"4","key":"21_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/vaccines9040359","volume":"9","author":"TTH Thi","year":"2021","unstructured":"Thi TTH et al (2021) Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines 9(4):359. https:\/\/doi.org\/10.3390\/vaccines9040359","journal-title":"Vaccines"},{"key":"21_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/0167-7799(90)90220-R","volume":"8","author":"R Jorgensen","year":"1990","unstructured":"Jorgensen R (1990) Altered gene expression in plants due totrans interactions between homologous genes. Trends Biotechnol 8:340\u2013344. https:\/\/doi.org\/10.1016\/0167-7799(90)90220-R","journal-title":"Trends Biotechnol"},{"key":"21_CR18","doi-asserted-by":"publisher","unstructured":"Fire A et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806\u2013811. https:\/\/doi.org\/10.1038\/35888","DOI":"10.1038\/35888"},{"key":"21_CR19","doi-asserted-by":"publisher","unstructured":"Stark GR et al (1998) How cells respond to interferons. Annu Rev Biochem 67:227\u2013264.\u00a0https:\/\/doi.org\/10.1146\/annurev.biochem.67.1.227","DOI":"10.1146\/annurev.biochem.67.1.227"},{"issue":"6836","key":"21_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494\u2013498. https:\/\/doi.org\/10.1038\/35078107","journal-title":"Nature"},{"issue":"1","key":"21_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","volume":"118","author":"H Zhang","year":"2004","unstructured":"Zhang H et al (2004) Single processing center models for human dicer and bacterial RNase III. Cell 118(1):57\u201368. https:\/\/doi.org\/10.1016\/j.cell.2004.06.017","journal-title":"Cell"},{"issue":"6775","key":"21_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/35005107","volume":"404","author":"SM Hammond","year":"2000","unstructured":"Hammond SM, Bernstein E, Beach D, Hannon GJ (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404(6775):293\u2013296. https:\/\/doi.org\/10.1038\/35005107","journal-title":"Nature"},{"issue":"10","key":"21_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0968-0004(00)01641-8","volume":"25","author":"L Cerutti","year":"2000","unstructured":"Cerutti L, Mian N, Bateman A (2000) Domains in gene silencing and cell differentiation proteins: the novel PAZ domain and redefinition of the Piwi domain. Trends Biochem Sci 25(10):481\u2013482. https:\/\/doi.org\/10.1016\/S0968-0004(00)01641-8","journal-title":"Trends Biochem Sci"},{"issue":"21","key":"21_CR24","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1101\/gad.1026102","volume":"16","author":"MA Carmell","year":"2002","unstructured":"Carmell MA, Xuan Z, Zhang MQ, Hannon GJ (2002) The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 16(21):2733\u20132742. https:\/\/doi.org\/10.1101\/gad.1026102","journal-title":"Genes Dev"},{"issue":"5689","key":"21_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1126\/science.1102513","volume":"305","author":"J Liu","year":"2004","unstructured":"Liu J et al (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305(5689):1437\u20131441. https:\/\/doi.org\/10.1126\/science.1102513","journal-title":"Science"},{"issue":"2","key":"21_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tibs.2004.12.007","volume":"30","author":"G Tang","year":"2005","unstructured":"Tang G (2005) siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 30(2):106\u2013114. https:\/\/doi.org\/10.1016\/j.tibs.2004.12.007","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"21_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ajps.2018.12.005","volume":"14","author":"MAG Raja","year":"2019","unstructured":"Raja MAG, Katas H, Amjad MW (2019) Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA. Asian J Pharm Sci 14(5):497\u2013510. https:\/\/doi.org\/10.1016\/j.ajps.2018.12.005","journal-title":"Asian J Pharm Sci"},{"key":"21_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102239","volume":"29","author":"MA Subhan","year":"2020","unstructured":"Subhan MA, Torchilin V (2020) siRNA based drug design, quality, delivery and clinical translation. Nanomedicine 29:102239. https:\/\/doi.org\/10.1016\/j.nano.2020.102239","journal-title":"Nanomedicine"},{"key":"21_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"W Alshaer","year":"2021","unstructured":"Alshaer W et al (2021) siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol 905:174178. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174178","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"21_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","volume":"55","author":"I Ahn","year":"2023","unstructured":"Ahn I, Kang CS, Han J (2023) Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med 55(7):1283\u20131292. https:\/\/doi.org\/10.1038\/s12276-023-00998-y","journal-title":"Exp Mol Med"},{"issue":"1","key":"21_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","volume":"51","author":"DS Goldfarb","year":"2023","unstructured":"Goldfarb DS et al (2023) Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Urolithiasis 51(1):80. https:\/\/doi.org\/10.1007\/s00240-023-01453-3","journal-title":"Urolithiasis"},{"issue":"5589","key":"21_CR32","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1126\/science.1073827","volume":"297","author":"G Hutv\u00e1gner","year":"2002","unstructured":"Hutv\u00e1gner G, Zamore PD (2002) A microRNA in a multiple-turnover RNAi enzyme complex. Science 297(5589):2056\u20132060. https:\/\/doi.org\/10.1126\/science.1073827","journal-title":"Science"},{"issue":"3","key":"21_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tcb.2006.12.007","volume":"17","author":"RS Pillai","year":"2007","unstructured":"Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17(3):118\u2013126. https:\/\/doi.org\/10.1016\/j.tcb.2006.12.007","journal-title":"Trends Cell Biol"},{"issue":"17","key":"21_CR34","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","volume":"21","author":"Y Lee","year":"2002","unstructured":"Lee Y (2002) MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21(17):4663\u20134670. https:\/\/doi.org\/10.1093\/emboj\/cdf476","journal-title":"EMBO J"},{"issue":"5654","key":"21_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/science.1090599","volume":"303","author":"E Lund","year":"2004","unstructured":"Lund E et al (2004) Nuclear export of microRNA precursors. Science 303(5654):95\u201398. https:\/\/doi.org\/10.1126\/science.1090599","journal-title":"Science"},{"issue":"5531","key":"21_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1062961","volume":"293","author":"G Hutv\u00e1gner","year":"2001","unstructured":"Hutv\u00e1gner G et al (2001) A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science 293(5531):834\u2013838. https:\/\/doi.org\/10.1126\/science.1062961","journal-title":"Science"},{"issue":"4","key":"21_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"D Carroll","year":"2011","unstructured":"Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188(4):773\u2013782. https:\/\/doi.org\/10.1534\/genetics.111.131433","journal-title":"Genetics"},{"issue":"5","key":"21_CR38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.copbio.2012.01.013","volume":"23","author":"C Mussolino","year":"2012","unstructured":"Mussolino C, Cathomen T (2012) TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol 23(5):644\u2013650. https:\/\/doi.org\/10.1016\/j.copbio.2012.01.013","journal-title":"Curr Opin Biotechnol"},{"key":"21_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mib.2017.05.008","volume":"37","author":"EV Koonin","year":"2017","unstructured":"Koonin EV, Makarova KS, Zhang F (2017) Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol 37:67\u201378. https:\/\/doi.org\/10.1016\/j.mib.2017.05.008","journal-title":"Curr Opin Microbiol"},{"issue":"6121","key":"21_CR40","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong L et al (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819\u2013823. https:\/\/doi.org\/10.1126\/science.1231143","journal-title":"Science"},{"issue":"3","key":"21_CR41","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","volume":"163","author":"B Zetsche","year":"2015","unstructured":"Zetsche B et al (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163(3):759\u2013771. https:\/\/doi.org\/10.1016\/j.cell.2015.09.038","journal-title":"Cell"},{"issue":"39","key":"21_CR42","doi-asserted-by":"publisher","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","volume":"109","author":"G Gasiunas","year":"2012","unstructured":"Gasiunas G, Barrangou R, Horvath P, Siksnys V (2012) Cas9\u2013crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci 109(39):E2579. https:\/\/doi.org\/10.1073\/pnas.1208507109","journal-title":"Proc Natl Acad Sci"},{"issue":"6096","key":"21_CR43","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M et al (2012) A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829","journal-title":"Science"},{"issue":"2","key":"21_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","volume":"36","author":"Z Glass","year":"2018","unstructured":"Glass Z, Lee M, Li Y, Xu Q (2018) Engineering the delivery system for CRISPR-based genome editing. Trends Biotechnol 36(2):173\u2013185. https:\/\/doi.org\/10.1016\/j.tibtech.2017.11.006","journal-title":"Trends Biotechnol"},{"issue":"9\u201310","key":"21_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/hum.2023.29241.bfs","volume":"34","author":"A Philippidis","year":"2023","unstructured":"Philippidis A (2023) CRISPR therapeutics, vertex complete rolling biologics license applications for exa-cel in sickle cell disease, beta thalassemia. Hum Gene Ther 34(9\u201310):341\u2013344. https:\/\/doi.org\/10.1089\/hum.2023.29241.bfs","journal-title":"Hum Gene Ther"},{"issue":"1","key":"21_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9\u201321. https:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"21_CR47","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1073\/pnas.74.10.4370","volume":"74","author":"BM Paterson","year":"1977","unstructured":"Paterson BM, Roberts BE, Kuff EL (1977) Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci 74(10):4370\u20134374. https:\/\/doi.org\/10.1073\/pnas.74.10.4370","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"21_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/nat.2016.0656","volume":"27","author":"ST Crooke","year":"2017","unstructured":"Crooke ST (2017) Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther 27(2):70\u201377. https:\/\/doi.org\/10.1089\/nat.2016.0656","journal-title":"Nucleic Acid Ther"},{"key":"21_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/978-1-4939-8651-4_26","volume-title":"Exon skipping and inclusion therapies","author":"NN Singh","year":"2018","unstructured":"Singh NN, Luo D, Singh RN (2018) Pre-mRNA splicing modulation by antisense oligonucleotides. In: Yokota T, Maruyama R (eds) Exon skipping and inclusion therapies, vol 1828. Springer New York, New York, pp 415\u2013437"},{"issue":"10","key":"21_CR50","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ymthe.2019.06.016","volume":"27","author":"S Sasaki","year":"2019","unstructured":"Sasaki S et al (2019) Steric inhibition of 5\u2032 UTR regulatory elements results in upregulation of human CFTR. Mol Ther 27(10):1749\u20131757. https:\/\/doi.org\/10.1016\/j.ymthe.2019.06.016","journal-title":"Mol Ther"},{"issue":"10","key":"21_CR51","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1039\/C4MD00184B","volume":"5","author":"VK Sharma","year":"2014","unstructured":"Sharma VK, Sharma RK, Singh SK (2014) Antisense oligonucleotides: modifications and clinical trials. Med Chem Commun 5(10):1454\u20131471. https:\/\/doi.org\/10.1039\/C4MD00184B","journal-title":"Med Chem Commun"},{"issue":"6","key":"21_CR52","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli M, Manoharan M (2023) Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 51(6):2529\u20132573. https:\/\/doi.org\/10.1093\/nar\/gkad067","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"21_CR53","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","volume":"5","author":"CR Ireson","year":"2006","unstructured":"Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5(12):2957\u20132962. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0172","journal-title":"Mol Cancer Ther"},{"key":"21_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2021.101003","volume":"81","author":"M Pandey","year":"2021","unstructured":"Pandey M et al (2021) From bench side to clinic: potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Asp Med 81:101003. https:\/\/doi.org\/10.1016\/j.mam.2021.101003","journal-title":"Mol Asp Med"},{"key":"21_CR55","doi-asserted-by":"publisher","unstructured":"Gold L, Singer B, He Y-Y, Brody E (1997) SELEX and the evolution of genomes. Curr Opin Genet Dev 7(6):848\u2013851. https:\/\/doi.org\/10.1016\/S0959-437X(97)80050-0","DOI":"10.1016\/S0959-437X(97)80050-0"},{"issue":"2","key":"21_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00006982-200204000-00002","volume":"22","author":"The Eyetech Study G","year":"2002","unstructured":"The Eyetech Study G (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22(2):143\u2013152. https:\/\/doi.org\/10.1097\/00006982-200204000-00002","journal-title":"Retina"},{"issue":"4","key":"21_CR57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/sj.gt.3302900","volume":"14","author":"NS Que-Gewirth","year":"2007","unstructured":"Que-Gewirth NS, Sullenger BA (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther 14(4):283\u2013291. https:\/\/doi.org\/10.1038\/sj.gt.3302900","journal-title":"Gene Ther"},{"issue":"1","key":"21_CR58","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0378-4347(99)00285-6","volume":"732","author":"CE Tucker","year":"1999","unstructured":"Tucker CE et al (1999) Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732(1):203\u2013212. https:\/\/doi.org\/10.1016\/S0378-4347(99)00285-6","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"1","key":"21_CR59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","volume":"57","author":"SM Nimjee","year":"2017","unstructured":"Nimjee SM, White RR, Becker RC, Sullenger BA (2017) Aptamers as therapeutics. Annu Rev Pharmacol Toxicol 57(1):61\u201379. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104558","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4949","key":"21_CR60","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949):1465\u20131468. https:\/\/doi.org\/10.1126\/science.1690918","journal-title":"Science"},{"issue":"1","key":"21_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","volume":"73","author":"MJ Hogan","year":"2022","unstructured":"Hogan MJ, Pardi N (2022) mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med 73(1):17\u201339. https:\/\/doi.org\/10.1146\/annurev-med-042420-112725","journal-title":"Annu Rev Med"},{"issue":"10","key":"21_CR62","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6 (2014) mRNA-based therapeutics\u2014developing a new class of drugs. Nat Rev Drug Discov 13(10):759\u2013780. https:\/\/doi.org\/10.1038\/nrd4278","journal-title":"Nat Rev Drug Discov"},{"key":"21_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.21","volume":"5","author":"AE Grier","year":"2016","unstructured":"Grier AE et al (2016) pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences. Mol Ther Nucleic Acids 5:e306. https:\/\/doi.org\/10.1038\/mtna.2016.21","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"21_CR64","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini Von Niessen","year":"2019","unstructured":"Orlandini Von Niessen AG et al (2019) Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening. Mol Ther 27(4):824\u2013836. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.011","journal-title":"Mol Ther"},{"issue":"7","key":"21_CR65","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"PJ Sample","year":"2019","unstructured":"Sample PJ et al (2019) Human 5\u2032 UTR design and variant effect prediction from a massively parallel translation assay. Nat Biotechnol 37(7):803\u2013809. https:\/\/doi.org\/10.1038\/s41587-019-0164-5","journal-title":"Nat Biotechnol"},{"issue":"3\u20134","key":"21_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom K, Van Den Berg F, Arbuthnot P (2021) Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28(3\u20134):117\u2013129. https:\/\/doi.org\/10.1038\/s41434-020-00204-y","journal-title":"Gene Ther"},{"key":"21_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.virusres.2015.01.016","volume":"206","author":"JL Hyde","year":"2015","unstructured":"Hyde JL et al (2015) The 5\u2032 and 3\u2032 ends of alphavirus RNAs \u2013 non-coding is not non-functional. Virus Res 206:99\u2013107. https:\/\/doi.org\/10.1016\/j.virusres.2015.01.016","journal-title":"Virus Res"},{"issue":"2","key":"21_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1261\/rna.048272.114","volume":"21","author":"Y Wang","year":"2015","unstructured":"Wang Y, Wang Z (2015) Efficient backsplicing produces translatable circular mRNAs. RNA 21(2):172\u2013179. https:\/\/doi.org\/10.1261\/rna.048272.114","journal-title":"RNA"},{"issue":"1","key":"21_CR69","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft RA, Kowalski PS, Anderson DG (2018) Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun 9(1):2629. https:\/\/doi.org\/10.1038\/s41467-018-05096-6","journal-title":"Nat Commun"},{"issue":"4","key":"21_CR70","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","volume":"136","author":"J Houseley","year":"2009","unstructured":"Houseley J, Tollervey D (2009) The many pathways of RNA degradation. Cell 136(4):763\u2013776. https:\/\/doi.org\/10.1016\/j.cell.2009.01.019","journal-title":"Cell"},{"key":"21_CR71","doi-asserted-by":"publisher","unstructured":"Hueso M et al (2021) ncRNAs in therapeutics: challenges and limitations in nucleic acid-based drug delivery. Int J Mol Sci 22(21). https:\/\/doi.org\/10.3390\/ijms222111596","DOI":"10.3390\/ijms222111596"},{"issue":"2","key":"21_CR72","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jconrel.2012.04.008","volume":"161","author":"M Giacca","year":"2012","unstructured":"Giacca M, Zacchigna S (2012) Virus-mediated gene delivery for human gene therapy. J Control Release 161(2):377\u2013388. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.008","journal-title":"J Control Release"},{"issue":"42","key":"21_CR73","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1016\/j.vaccine.2007.08.016","volume":"25","author":"EA Reap","year":"2007","unstructured":"Reap EA et al (2007) Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25(42):7441\u20137449. https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.016","journal-title":"Vaccine"},{"issue":"3","key":"21_CR74","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/gt.2009.148","volume":"17","author":"S Nayak","year":"2010","unstructured":"Nayak S, Herzog RW (2010) Progress and prospects: immune responses to viral vectors. Gene Ther 17(3):295\u2013304. https:\/\/doi.org\/10.1038\/gt.2009.148","journal-title":"Gene Ther"},{"issue":"3","key":"21_CR75","first-page":"262","volume":"3","author":"P Qiu","year":"1996","unstructured":"Qiu P, Ziegelhoffer P, Sun J, Yang NS (1996) Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther 3(3):262\u2013268","journal-title":"Gene Ther"},{"issue":"1","key":"21_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.v98.1.49","volume":"98","author":"VF Van Tendeloo","year":"2001","unstructured":"Van Tendeloo VF et al (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98(1):49\u201356. https:\/\/doi.org\/10.1182\/blood.v98.1.49","journal-title":"Blood"},{"issue":"3","key":"21_CR77","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1039\/c8tx00005k","volume":"7","author":"S Cui","year":"2018","unstructured":"Cui S et al (2018) Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol Res (Camb) 7(3):473\u2013479. https:\/\/doi.org\/10.1039\/c8tx00005k","journal-title":"Toxicol Res (Camb)"},{"key":"21_CR78","doi-asserted-by":"publisher","unstructured":"Wasungu L, Hoekstra D (2006) Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 116(2):255\u2013264. https:\/\/doi.org\/10.1016\/j.jconrel.2006.06.024","DOI":"10.1016\/j.jconrel.2006.06.024"},{"issue":"1\u20132","key":"21_CR79","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s0005-2736(00)00343-6","volume":"1510","author":"SC Semple","year":"2001","unstructured":"Semple SC et al (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510(1\u20132):152\u2013166. https:\/\/doi.org\/10.1016\/s0005-2736(00)00343-6","journal-title":"Biochim Biophys Acta"},{"key":"21_CR80","doi-asserted-by":"publisher","unstructured":"Yavuz A et al (2023) DLin-MC3-containing mRNA lipid nanoparticles induce an antibody Th2-biased immune response polarization in a delivery route-dependent manner in mice. Pharmaceutics 15(3). https:\/\/doi.org\/10.3390\/pharmaceutics15031009","DOI":"10.3390\/pharmaceutics15031009"},{"issue":"48","key":"21_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202200906","volume":"28","author":"F Saadati","year":"2022","unstructured":"Saadati F, Cammarone S, Ciufolini MA (2022) A route to lipid ALC-0315: a key component of a COVID-19 mRNA vaccine. Chemistry 28(48):e202200906. https:\/\/doi.org\/10.1002\/chem.202200906","journal-title":"Chemistry"},{"key":"21_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2021.100424","volume":"41","author":"Y Suzuki","year":"2021","unstructured":"Suzuki Y, Ishihara H (2021) Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metab Pharmacokinet 41:100424. https:\/\/doi.org\/10.1016\/j.dmpk.2021.100424","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"21_CR83","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.xphs.2022.12.026","volume":"112","author":"M Kawaguchi","year":"2023","unstructured":"Kawaguchi M et al (2023) Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice. J Pharm Sci 112(5):1401\u20131410. https:\/\/doi.org\/10.1016\/j.xphs.2022.12.026","journal-title":"J Pharm Sci"},{"key":"21_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen C et al (2022) The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev 188:114416. https:\/\/doi.org\/10.1016\/j.addr.2022.114416","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"21_CR85","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","volume":"5","author":"YY Tam","year":"2013","unstructured":"Tam YY, Chen S, Cullis PR (2013) Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5(3):498\u2013507. https:\/\/doi.org\/10.3390\/pharmaceutics5030498","journal-title":"Pharmaceutics"},{"issue":"1","key":"21_CR86","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","volume":"9","author":"N Veiga","year":"2018","unstructured":"Veiga N et al (2018) Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun 9(1):4493. https:\/\/doi.org\/10.1038\/s41467-018-06936-1","journal-title":"Nat Commun"},{"key":"21_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105618","volume":"215","author":"J Yi","year":"2023","unstructured":"Yi J et al (2023) Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models. Antivir Res 215:105618. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105618","journal-title":"Antivir Res"},{"key":"21_CR88","doi-asserted-by":"publisher","unstructured":"Qiu M et al (2022) Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 119(8). https:\/\/doi.org\/10.1073\/pnas.2116271119","DOI":"10.1073\/pnas.2116271119"},{"issue":"9","key":"21_CR89","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","volume":"5","author":"R Goswami","year":"2019","unstructured":"Goswami R et al (2019) Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines. ACS Infect Dis 5(9):1546\u20131558. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00084","journal-title":"ACS Infect Dis"},{"issue":"9","key":"21_CR90","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.bbamem.2012.05.017","volume":"1818","author":"D Pozzi","year":"2012","unstructured":"Pozzi D et al (2012) Transfection efficiency boost of cholesterol-containing lipoplexes. Biochim Biophys Acta 1818(9):2335\u20132343. https:\/\/doi.org\/10.1016\/j.bbamem.2012.05.017","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"21_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0300-9084(87)90270-7","volume":"69","author":"C Esnault-Dupuy","year":"1987","unstructured":"Esnault-Dupuy C et al (1987) The relationship between HDL-, LDL-, liposomes-free cholesterol, biliary cholesterol and bile salts in the rat. Biochimie 69(1):45\u201352. https:\/\/doi.org\/10.1016\/0300-9084(87)90270-7","journal-title":"Biochimie"},{"issue":"22","key":"21_CR92","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2174\/1381612821666150531164540","volume":"21","author":"HY Xue","year":"2015","unstructured":"Xue HY, Guo P, Wen WC, Wong HL (2015) Lipid-based nanocarriers for RNA delivery. Curr Pharm Des 21(22):3140\u20133147. https:\/\/doi.org\/10.2174\/1381612821666150531164540","journal-title":"Curr Pharm Des"},{"issue":"1","key":"21_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbrc.2004.12.137","volume":"328","author":"X Yan","year":"2005","unstructured":"Yan X et al (2005) The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 328(1):57\u201362. https:\/\/doi.org\/10.1016\/j.bbrc.2004.12.137","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"21_CR94","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/mp100390w","volume":"8","author":"X Su","year":"2011","unstructured":"Su X, Fricke J, Kavanagh DG, Irvine DJ (2011) In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm 8(3):774\u2013787. https:\/\/doi.org\/10.1021\/mp100390w","journal-title":"Mol Pharm"},{"issue":"10","key":"21_CR95","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","volume":"1788","author":"SD Li","year":"2009","unstructured":"Li SD, Huang L (2009) Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 1788(10):2259\u20132266. https:\/\/doi.org\/10.1016\/j.bbamem.2009.06.022","journal-title":"Biochim Biophys Acta"},{"key":"21_CR96","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N et al (2015) Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 217:345\u2013351. https:\/\/doi.org\/10.1016\/j.jconrel.2015.08.007","journal-title":"J Control Release"},{"issue":"3 Pt A","key":"21_CR97","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","volume":"85","author":"K Hadinoto","year":"2013","unstructured":"Hadinoto K, Sundaresan A, Cheow WS (2013) Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85(3 Pt A):427\u2013443. https:\/\/doi.org\/10.1016\/j.ejpb.2013.07.002","journal-title":"Eur J Pharm Biopharm"},{"key":"21_CR98","doi-asserted-by":"publisher","unstructured":"Siewert CD et al (2020) Hybrid biopolymer and lipid nanoparticles with improved transfection efficacy for mRNA. Cells 9(9). https:\/\/doi.org\/10.3390\/cells9092034","DOI":"10.3390\/cells9092034"},{"issue":"19","key":"21_CR99","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1021\/cr5006793","volume":"115","author":"U Lachelt","year":"2015","unstructured":"Lachelt U, Wagner E (2015) Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond). Chem Rev 115(19):11043\u201311078. https:\/\/doi.org\/10.1021\/cr5006793","journal-title":"Chem Rev"},{"key":"21_CR100","doi-asserted-by":"publisher","unstructured":"Miron-Barroso S et al (2022) Polymeric carriers for delivery of RNA cancer therapeutics. Noncoding RNA 8(4). https:\/\/doi.org\/10.3390\/ncrna8040058","DOI":"10.3390\/ncrna8040058"},{"issue":"5","key":"21_CR101","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/jgm.696","volume":"7","author":"A Akinc","year":"2005","unstructured":"Akinc A, Thomas M, Klibanov AM, Langer R (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 7(5):657\u2013663. https:\/\/doi.org\/10.1002\/jgm.696","journal-title":"J Gene Med"},{"key":"21_CR102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","volume":"156","author":"AS Piotrowski-Daspit","year":"2020","unstructured":"Piotrowski-Daspit AS, Kauffman AC, Bracaglia LG, Saltzman WM (2020) Polymeric vehicles for nucleic acid delivery. Adv Drug Deliv Rev 156:119\u2013132. https:\/\/doi.org\/10.1016\/j.addr.2020.06.014","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"21_CR103","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2011.08.011","volume":"157","author":"DK Jensen","year":"2012","unstructured":"Jensen DK et al (2012) Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 157(1):141\u2013148. https:\/\/doi.org\/10.1016\/j.jconrel.2011.08.011","journal-title":"J Control Release"},{"key":"21_CR104","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.2147\/Ijn.S209325","volume":"14","author":"N Tahir","year":"2019","unstructured":"Tahir N et al (2019) Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy. Int J Nanomedicine 14:4961\u20134974. https:\/\/doi.org\/10.2147\/Ijn.S209325","journal-title":"Int J Nanomedicine"},{"issue":"6","key":"21_CR105","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1039\/c1nr11188d","volume":"4","author":"YC Yeh","year":"2012","unstructured":"Yeh YC, Creran B, Rotello VM (2012) Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale 4(6):1871\u20131880. https:\/\/doi.org\/10.1039\/c1nr11188d","journal-title":"Nanoscale"},{"issue":"10","key":"21_CR106","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1021\/bc200172p","volume":"22","author":"WH Kong","year":"2011","unstructured":"Kong WH et al (2011) Multimerized siRNA cross-linked by gold nanoparticles. Bioconjug Chem 22(10):1962\u20131969. https:\/\/doi.org\/10.1021\/bc200172p","journal-title":"Bioconjug Chem"},{"issue":"7","key":"21_CR107","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/smll.200801334","volume":"5","author":"J Griffin","year":"2009","unstructured":"Griffin J et al (2009) Sequence-specific HCV RNA quantification using the size-dependent nonlinear optical properties of gold nanoparticles. Small 5(7):839\u2013845. https:\/\/doi.org\/10.1002\/smll.200801334","journal-title":"Small"},{"issue":"11","key":"21_CR108","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1039\/d0md00298d","volume":"11","author":"S Gulati","year":"2020","unstructured":"Gulati S et al (2020) Functionalized gold nanoparticles: promising and efficient diagnostic and therapeutic tools for HIV\/AIDS. RSC Med Chem 11(11):1252\u20131266. https:\/\/doi.org\/10.1039\/d0md00298d","journal-title":"RSC Med Chem"},{"key":"21_CR109","doi-asserted-by":"publisher","unstructured":"Lee JH et al (2018) Development of dual-pore coexisting branched silica nanoparticles for efficient gene-chemo cancer therapy. Small 14(7). https:\/\/doi.org\/10.1002\/smll.201702564","DOI":"10.1002\/smll.201702564"},{"issue":"19","key":"21_CR110","doi-asserted-by":"publisher","first-page":"7553","DOI":"10.1158\/0008-5472.CAN-10-2070","volume":"70","author":"M Kumar","year":"2010","unstructured":"Kumar M et al (2010) Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 70(19):7553\u20137561. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2070","journal-title":"Cancer Res"},{"issue":"3","key":"21_CR111","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","volume":"142","author":"J Li","year":"2010","unstructured":"Li J et al (2010) Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 142(3):416\u2013421. https:\/\/doi.org\/10.1016\/j.jconrel.2009.11.008","journal-title":"J Control Release"},{"issue":"14","key":"21_CR112","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1021\/ja4098862","volume":"136","author":"C He","year":"2014","unstructured":"He C, Lu K, Liu D, Lin W (2014) Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J Am Chem Soc 136(14):5181\u20135184. https:\/\/doi.org\/10.1021\/ja4098862","journal-title":"J Am Chem Soc"},{"key":"21_CR113","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fphar.2020.00697","volume":"11","author":"J Xie","year":"2020","unstructured":"Xie J et al (2020) Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol 11:697. https:\/\/doi.org\/10.3389\/fphar.2020.00697","journal-title":"Front Pharmacol"},{"issue":"7","key":"21_CR114","doi-asserted-by":"publisher","first-page":"ARTN 1800065","DOI":"10.1002\/adtp.201800065","volume":"1","author":"H Shin","year":"2018","unstructured":"Shin H et al (2018) Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles. Adv Ther-Germany 1(7):ARTN 1800065. https:\/\/doi.org\/10.1002\/adtp.201800065","journal-title":"Adv Ther-Germany"},{"key":"21_CR115","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/s0022-2836(64)80115-7","volume":"8","author":"AD Bangham","year":"1964","unstructured":"Bangham AD, Horne RW (1964) Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 8:660\u2013668. https:\/\/doi.org\/10.1016\/s0022-2836(64)80115-7","journal-title":"J Mol Biol"},{"issue":"5","key":"21_CR116","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/10611869408996816","volume":"2","author":"N Weiner","year":"1994","unstructured":"Weiner N et al (1994) Liposomes: a novel topical delivery system for pharmaceutical and cosmetic applications. J Drug Target 2(5):405\u2013410. https:\/\/doi.org\/10.3109\/10611869408996816","journal-title":"J Drug Target"},{"issue":"21","key":"21_CR117","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","volume":"84","author":"PL Felgner","year":"1987","unstructured":"Felgner PL et al (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84(21):7413\u20137417. https:\/\/doi.org\/10.1073\/pnas.84.21.7413","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"21_CR118","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM197609302951406","volume":"295","author":"G Gregoriadis","year":"1976","unstructured":"Gregoriadis G (1976) The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 295(14):765\u2013770. https:\/\/doi.org\/10.1056\/NEJM197609302951406","journal-title":"N Engl J Med"},{"issue":"13","key":"21_CR119","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM197609232951305","volume":"295","author":"G Gregoriadis","year":"1976","unstructured":"Gregoriadis G (1976) The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 295(13):704\u2013710. https:\/\/doi.org\/10.1056\/NEJM197609232951305","journal-title":"N Engl J Med"},{"key":"21_CR120","doi-asserted-by":"publisher","unstructured":"Pao SC, Chu MT, Hung SI (2022) Therapeutic vaccines targeting neoantigens to induce T-cell immunity against cancers. Pharmaceutics 14(4). https:\/\/doi.org\/10.3390\/pharmaceutics14040867","DOI":"10.3390\/pharmaceutics14040867"},{"issue":"3","key":"21_CR121","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2005.12.002","volume":"69","author":"BB Gowen","year":"2006","unstructured":"Gowen BB et al (2006) Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antivir Res 69(3):165\u2013172. https:\/\/doi.org\/10.1016\/j.antiviral.2005.12.002","journal-title":"Antivir Res"},{"issue":"7607","key":"21_CR122","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz LM et al (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396\u2013401. https:\/\/doi.org\/10.1038\/nature18300","journal-title":"Nature"},{"issue":"1","key":"21_CR123","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s13346-013-0158-7","volume":"4","author":"D Landesman-Milo","year":"2014","unstructured":"Landesman-Milo D, Peer D (2014) Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv Transl Res 4(1):96\u2013103. https:\/\/doi.org\/10.1007\/s13346-013-0158-7","journal-title":"Drug Deliv Transl Res"},{"issue":"12","key":"21_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.65","volume":"2","author":"RL Rungta","year":"2013","unstructured":"Rungta RL et al (2013) Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol Ther Nucleic Acids 2(12):e136. https:\/\/doi.org\/10.1038\/mtna.2013.65","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"21_CR125","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ (2017) Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25(7):1467\u20131475. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.013","journal-title":"Mol Ther"},{"issue":"32","key":"21_CR126","doi-asserted-by":"publisher","first-page":"12881","DOI":"10.1073\/pnas.1306529110","volume":"110","author":"CA Alabi","year":"2013","unstructured":"Alabi CA et al (2013) Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery. Proc Natl Acad Sci USA 110(32):12881\u201312886. https:\/\/doi.org\/10.1073\/pnas.1306529110","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR127","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead KA et al (2014) Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 5:4277. https:\/\/doi.org\/10.1038\/ncomms5277","journal-title":"Nat Commun"},{"issue":"2","key":"21_CR128","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S0006-3495(98)77593-9","volume":"75","author":"P Harvie","year":"1998","unstructured":"Harvie P, Wong FM, Bally MB (1998) Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040\u20131051. https:\/\/doi.org\/10.1016\/S0006-3495(98)77593-9","journal-title":"Biophys J"},{"issue":"8","key":"21_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau NM et al (2012) Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1(8):e37. https:\/\/doi.org\/10.1038\/mtna.2012.28","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"21_CR130","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1124\/jpet.104.078113","volume":"312","author":"SC Semple","year":"2005","unstructured":"Semple SC et al (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312(3):1020\u20131026. https:\/\/doi.org\/10.1124\/jpet.104.078113","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"21_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"BL Mui","year":"2013","unstructured":"Mui BL et al (2013) Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids 2(12):e139. https:\/\/doi.org\/10.1038\/mtna.2013.66","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"21_CR132","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/mt.2016.179","volume":"24","author":"H Wang","year":"2016","unstructured":"Wang H et al (2016) The Niemann-Pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA. Mol Ther 24(12):2100\u20132108. https:\/\/doi.org\/10.1038\/mt.2016.179","journal-title":"Mol Ther"},{"key":"21_CR133","doi-asserted-by":"publisher","unstructured":"Rosenblum D et al (2020) CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv 6(47). https:\/\/doi.org\/10.1126\/sciadv.abc9450","DOI":"10.1126\/sciadv.abc9450"},{"issue":"3","key":"21_CR134","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2007.09.004","volume":"123","author":"SD Li","year":"2007","unstructured":"Li SD, Huang L (2007) Non-viral is superior to viral gene delivery. J Control Release 123(3):181\u2013183. https:\/\/doi.org\/10.1016\/j.jconrel.2007.09.004","journal-title":"J Control Release"},{"issue":"2","key":"21_CR135","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejpb.2004.11.011","volume":"60","author":"U Lungwitz","year":"2005","unstructured":"Lungwitz U, Breunig M, Blunk T, Gopferich A (2005) Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60(2):247\u2013266. https:\/\/doi.org\/10.1016\/j.ejpb.2004.11.011","journal-title":"Eur J Pharm Biopharm"},{"key":"21_CR136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","volume":"10","author":"S Al-Halifa","year":"2019","unstructured":"Al-Halifa S et al (2019) Nanoparticle-based vaccines against respiratory viruses. Front Immunol 10:22. https:\/\/doi.org\/10.3389\/fimmu.2019.00022","journal-title":"Front Immunol"},{"key":"21_CR137","doi-asserted-by":"publisher","unstructured":"Mura P, Maestrelli F, Cirri M, Mennini N (2022) Multiple roles of chitosan in mucosal drug delivery: an updated review. Mar Drugs 20(5). https:\/\/doi.org\/10.3390\/md20050335","DOI":"10.3390\/md20050335"},{"issue":"4","key":"21_CR138","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/7385","volume":"5","author":"K Roy","year":"1999","unstructured":"Roy K, Mao HQ, Huang SK, Leong KW (1999) Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5(4):387\u2013391. https:\/\/doi.org\/10.1038\/7385","journal-title":"Nat Med"},{"issue":"3","key":"21_CR139","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.nano.2007.03.006","volume":"3","author":"N Nafee","year":"2007","unstructured":"Nafee N et al (2007) Chitosan-coated PLGA nanoparticles for DNA\/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 3(3):173\u2013183. https:\/\/doi.org\/10.1016\/j.nano.2007.03.006","journal-title":"Nanomedicine"},{"issue":"36","key":"21_CR140","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1073\/pnas.0703882104","volume":"104","author":"M Breunig","year":"2007","unstructured":"Breunig M, Lungwitz U, Liebl R, Goepferich A (2007) Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci USA 104(36):14454\u201314459. https:\/\/doi.org\/10.1073\/pnas.0703882104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"21_CR141","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.nano.2010.12.010","volume":"7","author":"F Perche","year":"2011","unstructured":"Perche F et al (2011) Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7(4):445\u2013453. https:\/\/doi.org\/10.1016\/j.nano.2010.12.010","journal-title":"Nanomedicine"},{"key":"21_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122171","volume":"626","author":"A Lokras","year":"2022","unstructured":"Lokras A et al (2022) Simultaneous quantification of multiple RNA cargos co-loaded into nanoparticle-based delivery systems. Int J Pharm 626:122171. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122171","journal-title":"Int J Pharm"},{"issue":"8","key":"21_CR143","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.nano.2013.04.010","volume":"9","author":"F Wang","year":"2013","unstructured":"Wang F et al (2013) The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine 9(8):1159\u20131168. https:\/\/doi.org\/10.1016\/j.nano.2013.04.010","journal-title":"Nanomedicine"},{"key":"21_CR144","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejpb.2017.07.014","volume":"120","author":"K Thanki","year":"2017","unstructured":"Thanki K et al (2017) Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: a quality by design-based approach. Eur J Pharm Biopharm 120:22\u201333. https:\/\/doi.org\/10.1016\/j.ejpb.2017.07.014","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"21_CR145","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/ma5020278","volume":"5","author":"DL Kirkpatrick","year":"2012","unstructured":"Kirkpatrick DL et al (2012) Carbon nanotubes: solution for the therapeutic delivery of siRNA? Materials (Basel) 5(2):278\u2013301. https:\/\/doi.org\/10.3390\/ma5020278","journal-title":"Materials (Basel)"},{"issue":"7149","key":"21_CR146","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nature05901","volume":"448","author":"P Kumar","year":"2007","unstructured":"Kumar P et al (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149):39\u201343. https:\/\/doi.org\/10.1038\/nature05901","journal-title":"Nature"},{"key":"21_CR147","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.omtn.2022.09.012","volume":"30","author":"T Samec","year":"2022","unstructured":"Samec T et al (2022) Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer. Mol Ther Nucleic Acids 30:95\u2013111. https:\/\/doi.org\/10.1016\/j.omtn.2022.09.012","journal-title":"Mol Ther Nucleic Acids"},{"key":"21_CR148","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1186\/1471-2407-14-748","volume":"14","author":"M Sebastian","year":"2014","unstructured":"Sebastian M et al (2014) Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer 14:748. https:\/\/doi.org\/10.1186\/1471-2407-14-748","journal-title":"BMC Cancer"},{"issue":"3","key":"21_CR149","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4103\/joacp.JOACP_349_15","volume":"33","author":"G Kapoor","year":"2017","unstructured":"Kapoor G, Saigal S, Elongavan A (2017) Action and resistance mechanisms of antibiotics: a guide for clinicians. J Anaesthesiol Clin Pharmacol 33(3):300\u2013305. https:\/\/doi.org\/10.4103\/joacp.JOACP_349_15","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"21_CR150","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jgar.2020.12.025","volume":"24","author":"LM Streicher","year":"2021","unstructured":"Streicher LM (2021) Exploring the future of infectious disease treatment in a post-antibiotic era: a comparative review of alternative therapeutics. J Glob Antimicrob Resist 24:285\u2013295. https:\/\/doi.org\/10.1016\/j.jgar.2020.12.025","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"21_CR151","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281\u2013297. https:\/\/doi.org\/10.1016\/s0092-8674(04)00045-5","journal-title":"Cell"},{"issue":"4","key":"21_CR152","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5483\/bmbrep.2014.47.4.040","volume":"47","author":"FY Gong","year":"2014","unstructured":"Gong FY et al (2014) siRNA-mediated gene silencing of MexB from the MexA-MexB-OprM efflux pump in Pseudomonas aeruginosa. BMB Rep 47(4):203\u2013208. https:\/\/doi.org\/10.5483\/bmbrep.2014.47.4.040","journal-title":"BMB Rep"},{"issue":"1","key":"21_CR153","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jac\/dki416","volume":"57","author":"K Yanagihara","year":"2006","unstructured":"Yanagihara K et al (2006) Effects of short interfering RNA against methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother 57(1):122\u2013126. https:\/\/doi.org\/10.1093\/jac\/dki416","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"21_CR154","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13567-020-00760-6","volume":"51","author":"S Menanteau-Ledouble","year":"2020","unstructured":"Menanteau-Ledouble S, Schachner O, Lawrence ML, El-Matbouli M (2020) Effects of siRNA silencing on the susceptibility of the fish cell line CHSE-214 to Yersinia ruckeri. Vet Res 51(1):45. https:\/\/doi.org\/10.1186\/s13567-020-00760-6","journal-title":"Vet Res"},{"key":"21_CR155","doi-asserted-by":"publisher","unstructured":"van Wijk XM et al (2017) Whole-genome sequencing of invasion-resistant cells identifies laminin alpha2 as a host factor for bacterial invasion. mBio 8(1). https:\/\/doi.org\/10.1128\/mBio.02128-16","DOI":"10.1128\/mBio.02128-16"},{"issue":"4","key":"21_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004549","volume":"11","author":"HL Tay","year":"2015","unstructured":"Tay HL et al (2015) Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog 11(4):e1004549. https:\/\/doi.org\/10.1371\/journal.ppat.1004549","journal-title":"PLoS Pathog"},{"issue":"6","key":"21_CR157","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jcf.2019.04.009","volume":"18","author":"S Malhotra","year":"2019","unstructured":"Malhotra S, Hayes D Jr, Wozniak DJ (2019) Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung. J Cyst Fibros 18(6):796\u2013803. https:\/\/doi.org\/10.1016\/j.jcf.2019.04.009","journal-title":"J Cyst Fibros"},{"key":"21_CR158","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3389\/fimmu.2017.01327","volume":"8","author":"F Huang","year":"2017","unstructured":"Huang F et al (2017) miR-148a-3p mediates notch signaling to promote the differentiation and M1 activation of macrophages. Front Immunol 8:1327. https:\/\/doi.org\/10.3389\/fimmu.2017.01327","journal-title":"Front Immunol"},{"issue":"4","key":"21_CR159","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cell.2009.01.043","volume":"136","author":"LS Waters","year":"2009","unstructured":"Waters LS, Storz G (2009) Regulatory RNAs in bacteria. Cell 136(4):615\u2013628. https:\/\/doi.org\/10.1016\/j.cell.2009.01.043","journal-title":"Cell"},{"issue":"1","key":"21_CR160","doi-asserted-by":"publisher","first-page":"8123","DOI":"10.1038\/s41598-019-44458-y","volume":"9","author":"P Ingle","year":"2019","unstructured":"Ingle P et al (2019) Generation of a fully erythromycin-sensitive strain of Clostridioides difficile using a novel CRISPR-Cas9 genome editing system. Sci Rep 9(1):8123. https:\/\/doi.org\/10.1038\/s41598-019-44458-y","journal-title":"Sci Rep"},{"key":"21_CR161","doi-asserted-by":"publisher","unstructured":"Mayorga-Ramos A et al (2023) CRISPR-Cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance. ACS Infect Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.2c00649","DOI":"10.1021\/acsinfecdis.2c00649"},{"issue":"7448","key":"21_CR162","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature12048","volume":"497","author":"TR Sampson","year":"2013","unstructured":"Sampson TR et al (2013) A CRISPR\/Cas system mediates bacterial innate immune evasion and virulence. Nature 497(7448):254\u2013257. https:\/\/doi.org\/10.1038\/nature12048","journal-title":"Nature"},{"issue":"1","key":"21_CR163","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1073\/pnas.97.1.418","volume":"97","author":"G Harth","year":"2000","unstructured":"Harth G et al (2000) Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate\/glutamine cell wall structure, and bacterial replication. Proc Natl Acad Sci USA 97(1):418\u2013423. https:\/\/doi.org\/10.1073\/pnas.97.1.418","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"21_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.62","volume":"2","author":"N Patenge","year":"2013","unstructured":"Patenge N et al (2013) Inhibition of growth and gene expression by PNA-peptide conjugates in Streptococcus pyogenes. Mol Ther Nucleic Acids 2(11):e132. https:\/\/doi.org\/10.1038\/mtna.2013.62","journal-title":"Mol Ther Nucleic Acids"},{"key":"21_CR165","doi-asserted-by":"publisher","unstructured":"Matchawong A, Srisawat C, Sangboonruang S, Tharinjaroen CS (2022) The ability of nuclease-resistant RNA aptamer against Streptococcus suis serotype 2, strain P1\/7 to reduce biofilm formation in vitro. Molecules 27(12). https:\/\/doi.org\/10.3390\/molecules27123894","DOI":"10.3390\/molecules27123894"},{"issue":"10","key":"21_CR166","doi-asserted-by":"publisher","first-page":"eadg1036","DOI":"10.1126\/sciadv.adg1036","volume":"9","author":"E Kon","year":"2023","unstructured":"Kon E et al (2023) A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. Sci Adv 9(10):eadg1036. https:\/\/doi.org\/10.1126\/sciadv.adg1036","journal-title":"Sci Adv"},{"issue":"3","key":"21_CR167","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1073\/pnas.0409028102","volume":"102","author":"SL Uprichard","year":"2005","unstructured":"Uprichard SL, Boyd B, Althage A, Chisari FV (2005) Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 102(3):773\u2013778. https:\/\/doi.org\/10.1073\/pnas.0409028102","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR168","doi-asserted-by":"publisher","unstructured":"Tarn WY, Cheng Y, Ko SH, Huang LM (2021) Antisense oligonucleotide-based therapy of viral infections. Pharmaceutics 13(12). https:\/\/doi.org\/10.3390\/pharmaceutics13122015","DOI":"10.3390\/pharmaceutics13122015"},{"key":"21_CR169","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.omtn.2019.07.001","volume":"17","author":"M Takahashi","year":"2019","unstructured":"Takahashi M et al (2019) Dual mechanisms of action of self-delivering, anti-HIV-1 FANA oligonucleotides as a potential new approach to HIV therapy. Mol Ther Nucleic Acids 17:615\u2013625. https:\/\/doi.org\/10.1016\/j.omtn.2019.07.001","journal-title":"Mol Ther Nucleic Acids"},{"key":"21_CR170","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/srep00756","volume":"2","author":"AS Levina","year":"2012","unstructured":"Levina AS et al (2012) High-performance method for specific effect on nucleic acids in cells using TiO2~DNA nanocomposites. Sci Rep 2:756. https:\/\/doi.org\/10.1038\/srep00756","journal-title":"Sci Rep"},{"key":"21_CR171","doi-asserted-by":"publisher","first-page":"14991","DOI":"10.1038\/srep14991","volume":"5","author":"L Zhao","year":"2015","unstructured":"Zhao L et al (2015) Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells. Sci Rep 5:14991. https:\/\/doi.org\/10.1038\/srep14991","journal-title":"Sci Rep"},{"issue":"4","key":"21_CR172","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1128\/JVI.02091-10","volume":"85","author":"BL Heiss","year":"2011","unstructured":"Heiss BL, Maximova OA, Pletnev AG (2011) Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype. J Virol 85(4):1464\u20131472. https:\/\/doi.org\/10.1128\/JVI.02091-10","journal-title":"J Virol"},{"issue":"9","key":"21_CR173","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1086\/319857","volume":"183","author":"MN Fleeton","year":"2001","unstructured":"Fleeton MN et al (2001) Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 183(9):1395\u20131398. https:\/\/doi.org\/10.1086\/319857","journal-title":"J Infect Dis"},{"issue":"11","key":"21_CR174","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1586\/14787210.2013.845524","volume":"11","author":"MA Collier","year":"2013","unstructured":"Collier MA et al (2013) Delivery of host cell-directed therapeutics for intracellular pathogen clearance. Expert Rev Anti-Infect Ther 11(11):1225\u20131235. https:\/\/doi.org\/10.1586\/14787210.2013.845524","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"16","key":"21_CR175","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/0264-410x(94)90074-4","volume":"12","author":"X Zhou","year":"1994","unstructured":"Zhou X et al (1994) Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12(16):1510\u20131514. https:\/\/doi.org\/10.1016\/0264-410x(94)90074-4","journal-title":"Vaccine"},{"issue":"1","key":"21_CR176","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12929-019-0611-0","volume":"27","author":"S Afrasiabi","year":"2020","unstructured":"Afrasiabi S et al (2020) Therapeutic applications of nucleic acid aptamers in microbial infections. J Biomed Sci 27(1):6. https:\/\/doi.org\/10.1186\/s12929-019-0611-0","journal-title":"J Biomed Sci"},{"issue":"5","key":"21_CR177","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jb\/mvj095","volume":"139","author":"SC Gopinath","year":"2006","unstructured":"Gopinath SC, Sakamaki Y, Kawasaki K, Kumar PK (2006) An efficient RNA aptamer against human influenza B virus hemagglutinin. J Biochem 139(5):837\u2013846. https:\/\/doi.org\/10.1093\/jb\/mvj095","journal-title":"J Biochem"},{"issue":"47","key":"21_CR178","doi-asserted-by":"publisher","first-page":"8406","DOI":"10.1021\/bi400704d","volume":"52","author":"JM Binning","year":"2013","unstructured":"Binning JM et al (2013) Development of RNA aptamers targeting Ebola virus VP35. Biochemistry 52(47):8406\u20138419. https:\/\/doi.org\/10.1021\/bi400704d","journal-title":"Biochemistry"},{"issue":"1","key":"21_CR179","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1128\/JVI.02626-09","volume":"85","author":"D Ramalingam","year":"2011","unstructured":"Ramalingam D et al (2011) RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J Virol 85(1):305\u2013314. https:\/\/doi.org\/10.1128\/JVI.02626-09","journal-title":"J Virol"},{"issue":"3","key":"21_CR180","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.bbrc.2007.12.020","volume":"366","author":"KJ Jang","year":"2008","unstructured":"Jang KJ et al (2008) Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase\/Helicase. Biochem Biophys Res Commun 366(3):738\u2013744. https:\/\/doi.org\/10.1016\/j.bbrc.2007.12.020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"21_CR181","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.7150\/thno.23085","volume":"8","author":"J Zhou","year":"2018","unstructured":"Zhou J et al (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8(6):1575\u20131590. https:\/\/doi.org\/10.7150\/thno.23085","journal-title":"Theranostics"},{"key":"21_CR182","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina H, Misawa N, Kanemura Y, Koyanagi Y (2013) Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3:2510. https:\/\/doi.org\/10.1038\/srep02510","journal-title":"Sci Rep"},{"issue":"1","key":"21_CR183","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","volume":"20","author":"Y Wang","year":"2021","unstructured":"Wang Y et al (2021) mRNA vaccine: a potential therapeutic strategy. Mol Cancer 20(1):33. https:\/\/doi.org\/10.1186\/s12943-021-01311-z","journal-title":"Mol Cancer"},{"issue":"16","key":"21_CR184","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett KS et al (2020) Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med 383(16):1544\u20131555. https:\/\/doi.org\/10.1056\/NEJMoa2024671","journal-title":"N Engl J Med"},{"issue":"5","key":"21_CR185","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tim.2021.09.007","volume":"30","author":"A Bruch","year":"2022","unstructured":"Bruch A, Kelani AA, Blango MG (2022) RNA-based therapeutics to treat human fungal infections. Trends Microbiol 30(5):411\u2013420. https:\/\/doi.org\/10.1016\/j.tim.2021.09.007","journal-title":"Trends Microbiol"},{"issue":"3","key":"21_CR186","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11046-012-9539-6","volume":"174","author":"M Moazeni","year":"2012","unstructured":"Moazeni M et al (2012) RNA-mediated gene silencing in Candida albicans: inhibition of hyphae formation by use of RNAi technology. Mycopathologia 174(3):177\u2013185. https:\/\/doi.org\/10.1007\/s11046-012-9539-6","journal-title":"Mycopathologia"},{"key":"21_CR187","doi-asserted-by":"publisher","first-page":"16151","DOI":"10.1038\/nplants.2016.151","volume":"2","author":"M Wang","year":"2016","unstructured":"Wang M et al (2016) Bidirectional cross-kingdom RNAi and fungal uptake of external RNAs confer plant protection. Nat Plants 2:16151. https:\/\/doi.org\/10.1038\/nplants.2016.151","journal-title":"Nat Plants"},{"issue":"3","key":"21_CR188","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13693780601158779","volume":"45","author":"M Khatri","year":"2007","unstructured":"Khatri M, Rajam MV (2007) Targeting polyamines of Aspergillus nidulans by siRNA specific to fungal ornithine decarboxylase gene. Med Mycol 45(3):211\u2013220. https:\/\/doi.org\/10.1080\/13693780601158779","journal-title":"Med Mycol"},{"issue":"7","key":"21_CR189","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00196-22","volume":"90","author":"A Castellanos-Gonzalez","year":"2022","unstructured":"Castellanos-Gonzalez A, Sadiqova A, Ortega-Mendez J, White AC Jr (2022) RNA-based therapy for Cryptosporidium parvum infection: proof-of-concept studies. Infect Immun 90(7):e0019622. https:\/\/doi.org\/10.1128\/iai.00196-22","journal-title":"Infect Immun"},{"issue":"6","key":"21_CR190","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/mmi.12155","volume":"87","author":"M Hashimoto","year":"2013","unstructured":"Hashimoto M et al (2013) Inositol 1,4,5-trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist Trypanosoma cruzi. Mol Microbiol 87(6):1133\u20131150. https:\/\/doi.org\/10.1111\/mmi.12155","journal-title":"Mol Microbiol"},{"issue":"1","key":"21_CR191","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1038\/s41467-018-05041-7","volume":"9","author":"A Baeza Garcia","year":"2018","unstructured":"Baeza Garcia A et al (2018) Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat Commun 9(1):2714. https:\/\/doi.org\/10.1038\/s41467-018-05041-7","journal-title":"Nat Commun"},{"issue":"23","key":"21_CR192","doi-asserted-by":"publisher","first-page":"20756","DOI":"10.1074\/jbc.M111859200","volume":"277","author":"H Ulrich","year":"2002","unstructured":"Ulrich H, Magdesian MH, Alves MJ, Colli W (2002) In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 277(23):20756\u201320762. https:\/\/doi.org\/10.1074\/jbc.M111859200","journal-title":"J Biol Chem"},{"key":"21_CR193","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/3-540-27262-3_19","volume":"173","author":"HU Goringer","year":"2006","unstructured":"Goringer HU, Homann M, Zacharias M, Adler A (2006) RNA aptamers as potential pharmaceuticals against infections with African trypanosomes. Handb Exp Pharmacol 173:375\u2013393. https:\/\/doi.org\/10.1007\/3-540-27262-3_19","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"21_CR194","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00436-009-1583-x","volume":"105","author":"A Barfod","year":"2009","unstructured":"Barfod A, Persson T, Lindh J (2009) In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1. Parasitol Res 105(6):1557\u20131566. https:\/\/doi.org\/10.1007\/s00436-009-1583-x","journal-title":"Parasitol Res"},{"issue":"1","key":"21_CR195","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nbt.3439","volume":"34","author":"A Hammond","year":"2016","unstructured":"Hammond A et al (2016) A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector Anopheles gambiae. Nat Biotechnol 34(1):78\u201383. https:\/\/doi.org\/10.1038\/nbt.3439","journal-title":"Nat Biotechnol"},{"issue":"1","key":"21_CR196","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1074\/jbc.M109.041640","volume":"285","author":"SP O\u2019Hara","year":"2010","unstructured":"O\u2019Hara SP et al (2010) NFkappaB p50-CCAAT\/enhancer-binding protein beta (C\/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection. J Biol Chem 285(1):216\u2013225. https:\/\/doi.org\/10.1074\/jbc.M109.041640","journal-title":"J Biol Chem"},{"issue":"17","key":"21_CR197","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1073\/pnas.91.17.7859","volume":"91","author":"C Ramazeilles","year":"1994","unstructured":"Ramazeilles C et al (1994) Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis. Proc Natl Acad Sci USA 91(17):7859\u20137863. https:\/\/doi.org\/10.1073\/pnas.91.17.7859","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7810","key":"21_CR198","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","volume":"582","author":"DK Raj","year":"2020","unstructured":"Raj DK et al (2020) Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Nature 582(7810):104\u2013108. https:\/\/doi.org\/10.1038\/s41586-020-2220-1","journal-title":"Nature"},{"key":"21_CR199","doi-asserted-by":"publisher","unstructured":"Xu S, Yang K, Li R, Zhang L (2020) mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci 21(18). https:\/\/doi.org\/10.3390\/ijms21186582","DOI":"10.3390\/ijms21186582"},{"issue":"11","key":"21_CR200","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA (2021) mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 20(11):817\u2013838. https:\/\/doi.org\/10.1038\/s41573-021-00283-5","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"21_CR201","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1038\/s41467-022-33721-y","volume":"13","author":"RL Mayer","year":"2022","unstructured":"Mayer RL et al (2022) Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes. Nat Commun 13(1):6075. https:\/\/doi.org\/10.1038\/s41467-022-33721-y","journal-title":"Nat Commun"},{"issue":"7","key":"21_CR202","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/eji.1830230749","volume":"23","author":"F Martinon","year":"1993","unstructured":"Martinon F et al (1993) Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 23(7):1719\u20131722. https:\/\/doi.org\/10.1002\/eji.1830230749","journal-title":"Eur J Immunol"},{"issue":"8","key":"21_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.54","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele A et al (2013) Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2(8):e52. https:\/\/doi.org\/10.1038\/emi.2013.54","journal-title":"Emerg Microbes Infect"},{"issue":"29","key":"21_CR204","doi-asserted-by":"publisher","first-page":"E4133","DOI":"10.1073\/pnas.1600299113","volume":"113","author":"JS Chahal","year":"2016","unstructured":"Chahal JS et al (2016) Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 113(29):E4133\u2013E4142. https:\/\/doi.org\/10.1073\/pnas.1600299113","journal-title":"Proc Natl Acad Sci USA"},{"key":"21_CR205","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fmicb.2017.00605","volume":"8","author":"F Luo","year":"2017","unstructured":"Luo F et al (2017) Induction of protective immunity against toxoplasma gondii in mice by nucleoside triphosphate hydrolase-II (NTPase-II) self-amplifying RNA vaccine encapsulated in lipid nanoparticle (LNP). Front Microbiol 8:605. https:\/\/doi.org\/10.3389\/fmicb.2017.00605","journal-title":"Front Microbiol"},{"issue":"620","key":"21_CR206","doi-asserted-by":"publisher","first-page":"eabj9827","DOI":"10.1126\/scitranslmed.abj9827","volume":"13","author":"A Sajid","year":"2021","unstructured":"Sajid A et al (2021) mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Sci Transl Med 13(620):eabj9827. https:\/\/doi.org\/10.1126\/scitranslmed.abj9827","journal-title":"Sci Transl Med"},{"issue":"2","key":"21_CR207","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","volume":"35","author":"G Maruggi","year":"2017","unstructured":"Maruggi G et al (2017) Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35(2):361\u2013368. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.040","journal-title":"Vaccine"},{"key":"21_CR208","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1472-6750-10-77","volume":"10","author":"JC Lorenzi","year":"2010","unstructured":"Lorenzi JC et al (2010) Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol 10:77. https:\/\/doi.org\/10.1186\/1472-6750-10-77","journal-title":"BMC Biotechnol"},{"issue":"10","key":"21_CR209","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1128\/AAC.49.10.4052-4060.2005","volume":"49","author":"Q Pan","year":"2005","unstructured":"Pan Q et al (2005) Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob Agents Chemother 49(10):4052\u20134060. https:\/\/doi.org\/10.1128\/AAC.49.10.4052-4060.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"21_CR210","doi-asserted-by":"publisher","unstructured":"Naveed M et al (2022) Designing mRNA- and peptide-based vaccine construct against emerging multidrug-resistant Citrobacter freundii: a computational-based subtractive proteomics approach. Medicina (Kaunas) 58(10). https:\/\/doi.org\/10.3390\/medicina58101356","DOI":"10.3390\/medicina58101356"},{"key":"21_CR211","doi-asserted-by":"publisher","unstructured":"Larsen SE et al (2023) An RNA-based vaccine platform for use against Mycobacterium tuberculosis. Vaccines (Basel) 11(1). https:\/\/doi.org\/10.3390\/vaccines11010130","DOI":"10.3390\/vaccines11010130"},{"issue":"20","key":"21_CR212","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA et al (2020) An mRNA vaccine against SARS-CoV-2 \u2013 preliminary report. N Engl J Med 383(20):1920\u20131931. https:\/\/doi.org\/10.1056\/NEJMoa2022483","journal-title":"N Engl J Med"},{"key":"21_CR213","doi-asserted-by":"publisher","unstructured":"Awasthi S et al (2019) Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 4(39). https:\/\/doi.org\/10.1126\/sciimmunol.aaw7083","DOI":"10.1126\/sciimmunol.aaw7083"},{"issue":"1","key":"21_CR214","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi N et al (2018) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9(1):3361. https:\/\/doi.org\/10.1038\/s41467-018-05482-0","journal-title":"Nat Commun"},{"issue":"2","key":"21_CR215","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel AB et al (2018) Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther 26(2):446\u2013455. https:\/\/doi.org\/10.1016\/j.ymthe.2017.11.017","journal-title":"Mol Ther"},{"key":"21_CR216","doi-asserted-by":"publisher","unstructured":"Zhuang X et al (2020) mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines (Basel) 8(1). https:\/\/doi.org\/10.3390\/vaccines8010123","DOI":"10.3390\/vaccines8010123"},{"issue":"1","key":"21_CR217","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/JVI.01786-15","volume":"90","author":"M Brazzoli","year":"2016","unstructured":"Brazzoli M et al (2016) Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J Virol 90(1):332\u2013344. https:\/\/doi.org\/10.1128\/JVI.01786-15","journal-title":"J Virol"},{"issue":"6","key":"21_CR218","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner JM et al (2017) Modified mRNA vaccines protect against Zika virus infection. Cell 168(6):1114\u20131125 e1110. https:\/\/doi.org\/10.1016\/j.cell.2017.02.017","journal-title":"Cell"},{"key":"21_CR219","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","volume":"18","author":"JH Erasmus","year":"2020","unstructured":"Erasmus JH et al (2020) Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika virus infection. Mol Ther Methods Clin Dev 18:402\u2013414. https:\/\/doi.org\/10.1016\/j.omtm.2020.06.011","journal-title":"Mol Ther Methods Clin Dev"},{"key":"21_CR220","doi-asserted-by":"publisher","unstructured":"Kose N et al (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol 4(35). https:\/\/doi.org\/10.1126\/sciimmunol.aaw6647","DOI":"10.1126\/sciimmunol.aaw6647"},{"issue":"1","key":"21_CR221","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","volume":"5","author":"AS Espeseth","year":"2020","unstructured":"Espeseth AS et al (2020) Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. NPJ Vaccines 5(1):16. https:\/\/doi.org\/10.1038\/s41541-020-0163-z","journal-title":"NPJ Vaccines"},{"issue":"7853","key":"21_CR222","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel AB et al (2021) BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592(7853):283\u2013289. https:\/\/doi.org\/10.1038\/s41586-021-03275-y","journal-title":"Nature"},{"issue":"6561","key":"21_CR223","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett KS et al (2021) Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373(6561):eabj0299. https:\/\/doi.org\/10.1126\/science.abj0299","journal-title":"Science"},{"issue":"1","key":"21_CR224","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF McKay","year":"2020","unstructured":"McKay PF et al (2020) Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun 11(1):3523. https:\/\/doi.org\/10.1038\/s41467-020-17409-9","journal-title":"Nat Commun"},{"key":"21_CR225","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","volume":"15","author":"N Pardi","year":"2019","unstructured":"Pardi N et al (2019) Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques. Mol Ther Nucleic Acids 15:36\u201347. https:\/\/doi.org\/10.1016\/j.omtn.2019.03.003","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"21_CR226","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L et al (2021) Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med 384(11):1003\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2031738","journal-title":"N Engl J Med"},{"key":"21_CR227","doi-asserted-by":"publisher","first-page":"14630","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi N et al (2017) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8:14630. https:\/\/doi.org\/10.1038\/ncomms14630","journal-title":"Nat Commun"}],"container-title":["Methods in Molecular Biology","Intracellular Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3890-3_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T11:13:10Z","timestamp":1718709190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3890-3_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071638897","9781071638903"],"references-count":227,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3890-3_21","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"19 June 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}